Richard Francis
Principal executive officer pay for Richard Francis, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) FY2023–FY2025
Beat peersTSR 204% vs peer group 25% over FY2023–FY2025
Turnaround$100 invested moved from behind the peer group ($106.53 vs $124.97) to ahead ($323.42 vs $156.35) over FY2023–FY2025
Aligned: paid up as stock roseCAP $26,191,537→$54,984,668 while $100 invested went $106.53→$323.42
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $25.7M | $26.2M |
| FY2024 | $15.5M | $40.9M |
| FY2025 | $19.2M | $55.0M |
The company's "$100 invested" index ran $106.53 at FY2023 → $323.42 by FY2025 — an annualized return of 74.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 74.2%/yr at TEVA ( FY2023–FY2025). See the CEO track-record ranking for context.